These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29732393)

  • 1. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
    Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
    Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer.
    Mehta S; Xie J; Ionescu-Ittu R; Nie X; Kwong WJ
    Oncol Ther; 2023 Dec; 11(4):481-493. PubMed ID: 37715853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
    Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
    Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
    Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
    Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer.
    Beigi A; Vafaei-Nodeh S; Huang L; Sun SZ; Ko JJ
    Curr Oncol; 2021 Sep; 28(5):3812-3824. PubMed ID: 34677243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study.
    Shao C; He J; Stein K; Keefe S
    Curr Med Res Opin; 2020 Jul; 36(7):1187-1194. PubMed ID: 32314603
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
    Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
    Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
    J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
    Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
    Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
    Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
    Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
    Flannery K; Boyd M; Black-Shinn J; Robert N; Kamat AM
    Future Oncol; 2019 Apr; 15(12):1323-1334. PubMed ID: 30942088
    [No Abstract]   [Full Text] [Related]  

  • 17. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
    He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
    Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
    Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
    Gynecol Oncol Rep; 2022 Dec; 44(Suppl 1):101101. PubMed ID: 36506039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
    Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
    Gynecol Oncol Rep; 2022 Dec; 44():101121. PubMed ID: 36589508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.